Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product
US11147805B2 · kind B2 · utility
1Cited by
1References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 7, 2019 |
| Grant date | Oct 19, 2021 |
| Priority date | — |
| Expiry date | Feb 7, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/22
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are formulations for treating affective mood disorders. The formulations comprise one or more than one CB receptor agonist and one or more than one serine hydrolase enzyme inhibitor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.